 | Up a level |
Journal Article
Andergassen, U., Rack, B., Annecke, K., Forstbauer, H., Ruhland, F., Harbeck, N., Sommer, H., Friese, K., Janni, W. and Kiechle, M. (2010). Tumor Characteristics and Prognostic Factors in Nodal Positive Early Stage Breast Cancer of Obese Patients - Sub Analysis of the German ADEBAR Study. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Braun, M., Gluz, O., Nitz, U., Christgen, M., Kuemmel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Kates, R. E., Wuerstlein, R., Kreipe, H. -H. and Harbecks, N. (2016). Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer. Oncol. Res. Treat., 39. S. 2 - 3. BASEL: KARGER. ISSN 2296-5262
Harbeck, N., Gluz, O., Christgen, M., Braun, M., Kuemmel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Kates, R. E., Wuerstlein, R., de Haas, S. L., Kiermaier, A., Kreipe, H. H. and Nitz, U. (2016). Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Harbeck, N., Gluz, O., Kreipe, H. H., Christgen, M., Svedman, C., Shak, S., Hofmann, D., Kuemmel, S., Nuding, B., Rezai, M., Schumacher, C., Kusche, M., Forstbauer, H., Maass, N., Kraemer, S., Aktas, B., Mohrmann, S., Wuerstlein, R., Kates, R. E. and Nitz, U. (2013). Run-in phase of prospective WSG-ADAPT HR+/ HER2-trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Biehl, C. M., Schumacher, C., Malter, W., Aktas, B., Forstbauer, H., Tio, J., Grischke, E-M., Kolberg-Liedtke, C., de Haas, S., Deurloo, R. J., Kates, R. E., Zu, C. Eulenburg, Wuerstlein, R., Kreipe, H. and Gluz, O. (2021). Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial. Ann. Oncol., 32. S. S1285 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Schumacher, C., Potenberg, J., Tio, J., Aktas, B., Malter, W., Forstbauer, H., von Schumann, R., Just, M., Jozwiak, K., Hauptmann, M., Kates, R., Graeser, M., Wuerstlein, R. and Kreipe, H. (2020). De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab plus ET in early HR+/HER2+breast cancer (BC): ADAPT-TP survival results. Ann. Oncol., 31. S. S1146 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Harbeck, N., Nitz, U. A., Matthias, C., Kates, R., Braun, M., Kummel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Grischke, E-M, de Haas, S. L., Deurloo, R., Schumacher, J., Wuerstlein, R., Kreipe, H. H. and Gluz, O. (2017). The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 +/- endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC). Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Nitz, U. A., Gluz, O., Christgen, M., Grischke, E. -M, Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H. and Harbeck, N. (2017). De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel. Ann. Oncol., 28 (11). S. 2768 - 2773. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Nitz, U. A. D., Gluz, O., Christgen, M., Grischke, E. -M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H. and Harbeck, N. (2022). De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel (vol 28, pg 2768, 2017). Ann. Oncol., 33 (3). S. 355 - 356. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Nitz, U., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M. and Walter-Kirst, R. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J. Clin. Oncol., 37 (10). S. 799 - 811. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755